PE20011120A1 - Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad - Google Patents
Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidadInfo
- Publication number
- PE20011120A1 PE20011120A1 PE2001000014A PE2001000014A PE20011120A1 PE 20011120 A1 PE20011120 A1 PE 20011120A1 PE 2001000014 A PE2001000014 A PE 2001000014A PE 2001000014 A PE2001000014 A PE 2001000014A PE 20011120 A1 PE20011120 A1 PE 20011120A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- antagonists
- pharmaceutical compositions
- cardiovascular morbidity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE UN COMPUESTO DE FORMULA I; DONDE A ES CH2, NR; B, D Y E SON CH, N; Y ES FENILO, NAFTILO, CICLOALQUILO C3-C8, HETEROCICLO; Z1 ES -(CH2)pW(CH2)q, -O(CH2)pCR5R6, -O(CH2)pW(CH2)q, ENTRE OTROS; G ES NR7R8, GRUPO a; DONDE n ES 0-2, m ES 1-3; W ES CH2, CH=CH, O, NR2, S(O)n, ENTRE OTROS; R ES H, ALQUILO C1-C6, R2 Y R3 SON H, ALQUILO C1-C4,; R4 ES H, HALO, ALQUILO C1-C6, ALCOXI C1-C4, ALQUIL(C1-C4)TIO; ALQUIL(C1-C4)SULFINILO, ENTRE OTROS; R5 Y R6 SON ALQUILO C1-C8 O JUNTOS FORMAN UN CARBOCICLO C3-C10; R7 Y R8 SON FENILO, CARBOCICLO C3-C10, HETEROCICLO C3-C10, H, ALQUILO C1-C6, ENTRE OTROS; e ES 0-2, p ES 0-3, q ES 0-3. SON COMPUESTOS PREFERIDOS CIS-6-(4-FLUOROFENIL)-5-[4-(2-PIPERIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TETRAHIDRO-NAFTALEN-2-OL, (-)-CIS-6-FENIL-5-[4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TETRAHIDRO-NAFTALEN--2-OL, ENTRE OTROS. EL COMPUESTO I ES UN AGONISTA/ANTAGONISTA DE ESTROGENOS Y REDUCE EL RIESGO DE MORBILIDAD Y/O MORTALIDAD CARDIOVASCULAR, CANCER DE MAMA, OSTEOPOROSIS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17566300P | 2000-01-12 | 2000-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20011120A1 true PE20011120A1 (es) | 2001-11-05 |
Family
ID=22641136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000014A PE20011120A1 (es) | 2000-01-12 | 2001-01-08 | Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad |
Country Status (11)
Country | Link |
---|---|
US (1) | US20010056099A1 (es) |
EP (1) | EP1118323A3 (es) |
JP (1) | JP2001226265A (es) |
KR (1) | KR100402562B1 (es) |
AU (1) | AU1113101A (es) |
CA (1) | CA2331059A1 (es) |
CO (1) | CO5271696A1 (es) |
HU (1) | HUP0100119A3 (es) |
IL (1) | IL140801A0 (es) |
PE (1) | PE20011120A1 (es) |
ZA (1) | ZA200100276B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1296674A2 (en) * | 2000-07-06 | 2003-04-02 | Wyeth | Use of substituted indole compounds for increasing nitric oxide synthase activity |
TWI303990B (en) * | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
US7295691B2 (en) * | 2002-05-15 | 2007-11-13 | Ge Medical Systems Global Technology Company, Llc | Computer aided diagnosis of an image set |
JP2005060303A (ja) * | 2003-08-12 | 2005-03-10 | Sutaagen:Kk | 不動性骨粗鬆の治療または予防剤 |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
MX2007000481A (es) | 2004-07-14 | 2007-03-29 | Ptc Therapeutics Inc | Metodos para tratar hepatitis c. |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
CN101022802A (zh) | 2004-07-22 | 2007-08-22 | Ptc医疗公司 | 用于治疗丙型肝炎的噻吩并吡啶化合物 |
MX2012014431A (es) | 2010-06-10 | 2013-02-26 | Aragon Pharmaceuticals Inc | Modulares del receptor de estrogenos y usos de los mismos. |
WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
AU2016331065B2 (en) | 2015-10-01 | 2021-04-29 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs |
EP3386968A4 (en) | 2015-12-09 | 2019-09-25 | The Board of Trustees of the University of Illinois | BENZOTHIOPHEN-BASED SELECTIVE ESTROGEN RECEPTOR-DOWN-REGULATING PREPARATIONS |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EA201990187A1 (ru) | 2016-07-01 | 2019-07-31 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
AU2018217809A1 (en) | 2017-02-10 | 2019-08-22 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
AU2018291026B2 (en) | 2017-06-29 | 2022-09-01 | G1 Therapeutics, Inc. | Morphic forms of GIT38 and methods of manufacture thereof |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
JP2023509375A (ja) | 2019-12-20 | 2023-03-08 | シーフォー セラピューティクス, インコーポレイテッド | Egfrの分解のためのイソインドリノン及びインダゾール化合物 |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
-
2000
- 2000-12-27 CO CO00097926A patent/CO5271696A1/es not_active Application Discontinuation
-
2001
- 2001-01-08 IL IL14080101A patent/IL140801A0/xx unknown
- 2001-01-08 PE PE2001000014A patent/PE20011120A1/es not_active Application Discontinuation
- 2001-01-09 EP EP01300159A patent/EP1118323A3/en not_active Withdrawn
- 2001-01-10 AU AU11131/01A patent/AU1113101A/en not_active Abandoned
- 2001-01-10 CA CA002331059A patent/CA2331059A1/en not_active Abandoned
- 2001-01-10 US US09/757,817 patent/US20010056099A1/en not_active Abandoned
- 2001-01-10 ZA ZA200100276A patent/ZA200100276B/xx unknown
- 2001-01-10 KR KR10-2001-0001257A patent/KR100402562B1/ko not_active IP Right Cessation
- 2001-01-11 HU HU0100119A patent/HUP0100119A3/hu unknown
- 2001-01-12 JP JP2001005300A patent/JP2001226265A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL140801A0 (en) | 2002-02-10 |
ZA200100276B (en) | 2002-07-10 |
CO5271696A1 (es) | 2003-04-30 |
EP1118323A3 (en) | 2003-05-21 |
EP1118323A2 (en) | 2001-07-25 |
US20010056099A1 (en) | 2001-12-27 |
CA2331059A1 (en) | 2001-07-12 |
HU0100119D0 (en) | 2001-03-28 |
KR20010083102A (ko) | 2001-08-31 |
KR100402562B1 (ko) | 2003-10-17 |
HUP0100119A2 (en) | 2002-10-28 |
JP2001226265A (ja) | 2001-08-21 |
HUP0100119A3 (en) | 2004-04-28 |
AU1113101A (en) | 2001-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20011120A1 (es) | Composiciones farmaceuticas de agonistas/antagonistas de estrogenos para reducir la morbilidad cardiovascular y el riesgo de mortalidad | |
PE20011046A1 (es) | Composiciones y procedimientos para el tratamiento de afecciones que responden a estrogenos | |
PE20011294A1 (es) | Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol | |
CY1113395T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη | |
EA200201179A1 (ru) | Производные 2-аминокарбонил-9h-пурина | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR049578A1 (es) | Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas | |
AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
EA200201141A1 (ru) | Производные тропана, полезные для терапии | |
EA200200770A1 (ru) | Производные пурина | |
AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
DE60107449D1 (de) | Substituierte aminopropoxyarylderivate als lxr agonisten | |
CY1109915T1 (el) | Φαρμακευτικες συνθεσεις οιστρογονων μεσων | |
AR028952A1 (es) | Antagonistas receptores de trombina | |
AR050407A1 (es) | Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas | |
CY1107221T1 (el) | Παραγωγα τριαζολιου ως ανταγωνιστες υποδοχεα ταχυκινινης | |
AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
PA8581401A1 (es) | Compuestos de imedazopiridina como agonistas del receptor 5-ht4 | |
CO5630034A2 (es) | Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
UY25204A1 (es) | Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos | |
PE20020506A1 (es) | Derivados de pirazol fusionados como inhibidores de la proteina cinasa | |
PE20071254A1 (es) | Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion | |
EA199800912A1 (ru) | Дигидратная соль мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2(1н)-индол-2-она, фармацевтическая композиция и способ лечения психотического расстройства | |
AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
AR017864A1 (es) | Compuestos de 1-[aril o heteroaril]-4-[3-fenil, naftil o cicloalquil-metilen, carbonil o hidroximetil]-3-[fenil-propil]piperazina, que poseen actividadsobre los receptores 1a de la serotonina, composiciones farmaceuticas formuladas con dichos compuestos; compuestos intermediarios para la sintesisde |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |